Medartuum

Medartuum is a UK-based biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting G protein-coupled receptors (GPCRs). The company's primary research efforts are directed toward addressing significant unmet needs in the management of chronic pain and inflammatory conditions. By leveraging its expertise in GPCR pharmacology, Medartuum aims to develop highly selective candidates with improved safety and efficacy profiles compared to current standards of care. The company operates primarily in the pre-clinical stage, advancing its lead programs through early-stage validation and optimization.